Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: A 1H magnetic resonance spectroscopy study

Psychiatry Research - Neuroimaging

Volumn 222, Issue 1-2, 2014, Pages 75-83

  Husarova, Veronika ^a,b,c   Bittsansky, Michal ^a   Ondrejka, Igor ^a   Dobrota, Dusan ^a  

^a University Hospital in Martin   (Slovakia)

^b Bratislava   (Slovakia)

^c Martinska Fakultna Nemocnica   (Slovakia)

Author keywords

Choline; Glutamate; N Acetylaspartate

Indexed keywords

CHOLINE; GLUTAMATE; N-ACETYLASPARTATE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ASPARTIC ACID; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHOLINE; CREATINE; FEMALE; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METHYLPHENIDATE; NERVE FIBERS, MYELINATED; NERVE FIBERS, UNMYELINATED; PREFRONTAL CORTEX; PROPYLAMINES; TREATMENT OUTCOME;

EID: 84898783862     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2014.03.003     Document Type: Article

References (55)

1. American Association of Pediatrics Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000, 105:1158-1170.
2. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Archives of Disease in Childhood 2005, 90(Suppl. 1):i26-i29.
3. Biederman J., Mick E.O., Surman C., Doyle R., Hammerness P., Michel E., Martin J., Spencer T.J. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 2007, 7:49.
4. 1H-MRS study. Clinical Neuropharmacology 2003, 26:218-221.
5. Carrey N., MacMaster F.P., Sparkes S.J., Khan S.C., Kusumakar V. Glutamatergic changes with treatment in attention deficit hyperactivity disorder: a preliminary case series. Journal of Child and Adolescent Psychopharmacology 2002, 12:331-336.
6. Carrey N.J., MacMaster F.P., Gaudet L., Schmidt M.H. Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 2007, 17:11-17.
7. Castellanos F.X., Elia J., Kruesi M.J., Gulotta C.S., Mefford I.N., Potter W.Z., Ritchie G.F., Rapoport J.L. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Research 1994, 52:305-316.
8. Castellanos F.X., Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nature Reviews Neuroscience 2002, 3:617-628.
9. Chang K., Nayar D., Howe M., Rana M. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. Journal of Child and Adolescent Psychopharmacology 2009, 19:547-551.
10. Choong K.C., Shen R.Y. Methylphenidate restores ventral tegmental area dopamine neuron activity in prenatal ethanol-exposed rats by augmenting dopamine neurotransmission. Journal of Pharmacology and Experimental Therapeutics 2004, 309:444-451.
11. Cihak R. Anatomie 1997, 3. Grada publishing spol.s.r.o., Praha. 1st ed.
12. Courvoisie H., Hooper S.R., Fine C., Kwock L., Castillo M. Neurometabolic functioning and neuropsychological correlates in children with ADHD-H: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences 2004, 16:63-69.
13. Cusack B., Nelson A., Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994, 114:559-565.
14. Dopfner M., Steinhausen H.C., Coghill D., Dalsgaard S., Poole L., Ralston S.J., Rothenberger A., Group A.S. Cross-cultural reliability and validity of ADHD assessed by the ADHD rating scale in a pan-European study. European Child and Adolescent Psychiatry 2006, 15(Suppl. 1):I46-155.
15. Dresel S., Krause J., Krause K.H., LaFougere C., Brinkbaumer K., Kung H.F., Hahn K., Tatsch K. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. European Journal of Nuclear Medicine 2000, 27:1518-1524.
16. DuPaul G., Power T., Anastopoulos A. ADHD Rating Scale-IV. Checklist, Norms, and Clinical Interpretation 1998, The Guilford Press, New York.
17. Faraone S.V., Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biological Psychiatry 1998, 44:951-958.
18. Fayed N., Modrego P.J., Castillo J., Davila J. Evidence of brain dysfunction in attention deficit-hyperactivity disorder: a controlled study with proton magnetic resonance spectroscopy. Academic Radiology 2007, 14:1029-1035.
19. Gainetdinov R.R., Wetsel W.C., Jones S.R., Levin E.D., Jaber M., Caron M.G. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999, 283:397-401.
20. Garnock-Jones K.P., Keating G.M. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatric Drugs 2009, 11:203-226.
21. Gorelova N., Mulholland P.J., Chandler L.J., Seamans J.K. The glutamatergic component of the mesocortical pathway emanating from different subregions of the ventral midbrain. Cerebral Cortex 2012, 22:327-336.
22. Husarova V., Ondrejka I., Tonhajzerova I. Potential pathomechanisms of ADHD based on neurometabolite changes. Neuro-endocrinology Letters 2010, 31:438-445.
23. Jain R., Babcock T., Burtea T., Dirks B., Adeyi B., Scheckner B., Lasser R. Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. Child and Adolescent Psychiatry and Mental Health 2011, 5:35.
24. 1H-magnetic resonance spectroscopy study. Neuroscience Letters 2001, 315:45-48.
25. Kobayashi T., Washiyama K., Ikeda K. Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine. Neuropsychopharmacology 2010, 35:1560-1569.
26. Kronenberg G., Ende G., Alm B., Deuschle M., Heuser I., Colla M. Increased NAA and reduced choline levels in the anterior cingulum following chronic methylphenidate. A spectroscopic test-retest study in adult ADHD. European Archives of Psychiatry and Clinical Neuroscience 2008, 258:446-450.
27. Kukley M., Capetillo-Zarate E., Dietrich D. Vesicular glutamate release from axons in white matter. Nature Neuroscience 2007, 10:311-320.
28. Ledbetter M. Atomoxetine: a novel treatment for child and adult ADHD. Neuropsychiatric Disease and Treatment 2006, 2:455-466.
29. Levy F. Synaptic gating and ADHD: a biological theory of comorbidity of ADHD and anxiety. Neuropsychopharmacology 2004, 29:1589-1596.
30. Ludolph A.G., Udvardi P.T., Schaz U., Henes C., Adolph O., Weigt H.U., Fegert J.M., Boeckers T.M., Fohr K.J. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. British Journal of Pharmacology 2010, 160:283-291.
31. MacMaster F.P., Carrey N., Sparkes S., Kusumakar V. Proton spectroscopy in medication-free pediatric attention-deficit/hyperactivity disorder. Biological Psychiatry 2003, 53:184-187.
32. Madras B.K., Miller G.M., Fischman A.J. The dopamine transporter and attention-deficit/hyperactivity disorder. Biological Psychiatry 2005, 57:1397-1409.
33. Mason G.F., Krystal J.H. MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases. NMR Biomedicine 2006, 19:690-701.
34. Mattingly G.W., Weisler R.H., Young J., Adeyi B., Dirks B., Babcock T., Lasser R., Scheckner B., Goodman D.W. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 2013, 13:39.
35. Max J.E., Manes F.F., Robertson B.A., Mathews K., Fox P.T., Lancaster J. Prefrontal and executive attention network lesions and the development of attention-deficit/hyperactivity symptomatology. American Academy of Child and Adolescent Psychiatry 2005, 44:443-450.
36. Oades R.D., Sadile A.G., Sagvolden T., Viggiano D., Zuddas A., Devoto P., Aase H., Johansen E.B., Ruocco L.A., Russell V.A. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Developmental Science 2005, 8:122-131.
37. Pelham W.E., Gnagy E.M., Burrows-Maclean L., Williams A., Fabiano G.A., Morrisey S.M., Chronis A.M., Forehand G.L., Nguyen C.A., Hoffman M.T., Lock T.M., Fielbelkorn K., Coles E.K., Panahon C.J., Steiner R.L., Meichenbaum D.L., Onyango A.N., Morse G.D. Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001, 107:E105.
38. Podet A., Lee M.J., Swann A.C., Dafny N. Nucleus accumbens lesions modulate the effects of methylphenidate. Brain Research Bulletin 2010, 82:293-301.
39. Posner M.I., Petersen S.E. The attention system of the human brain. Annual Review of Neuroscience 1990, 13:25-42.
40. Prieto-Gomez B., Vazquez-Alvarez A.M., Martinez-Pena J.L., Reyes-Vazquez C., Yang P.B., Dafny N. Methylphenidate and amphetamine modulate differently the NMDA and AMPA glutamatergic transmission of dopaminergic neurons in the ventral tegmental area. Life Sciences 2005, 77:635-649.
41. Rakic P. Neurogenesis in adult primate neocortex: an evaluation of the evidence. Nature Reviews. Neuroscience 2002, 3:65-71.
42. Rigotti D.J., Inglese M., Gonen O. Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR American Journal of Neuroradiology 2007, 28:1843-1849.
43. Rubia K., Taylor E., Smith A.B., Oksanen H., Overmeyer S., Newman S. Neuropsychological analyses of impulsiveness in childhood hyperactivity. British Journal of Psychiatry 2001, 179:138-143.
44. Sagvolden T., Sergeant J.A. Attention deficit/hyperactivity disorder - from brain dysfunctions to behaviour. Behavioural Brain Research 1998, 94:1-10.
45. Soutullo C., Banaschewski T., Lecendreux M., Johnson M., Zuddas A., Anderson C., Civil R., Higgins N., Bloomfield R., Squires L.A., Coghill D.R. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs 2013, 27(9):743-751.
46. Szabo S.T., Blier P. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacology 2001, 25:845-857.
47. 1H MRSI of middle frontal gyrus in pediatric ADHD. Journal of Psychiatric Research 2013, 47:505-512.
48. Tehrani-Doost M., Moallemi S., Shahrivar Z. An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 2008, 18:179-184.
49. Volkow N.D., Wang G.J., Fowler J.S., Fischman M., Foltin R., Abumrad N.N., Gatley S.J., Logan J., Wong C., Gifford A., Ding Y.S., Hitzemann R., Pappas N. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sciences 1999, 65:PL7-12.
50. Wanchoo S.J., Swann A.C., Dafny N. Descending glutamatergic pathways of PFC are involved in acute and chronic action of methylphenidate. Brain Research 2009, 1301:68-79.
51. 1H magnetic resonance spectroscopy (MRS). Clinical Neuropharmacology 2012, 35:81-85.
52. Wolraich M.L., Greenhill L.L., Pelham W., Swanson J., Wilens T., Palumbo D., Atkins M., McBurnett K., Bukstein O., August G. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001, 108:883-892.
53. Yang P., Wu M.T., Dung S.S., Ko C.W. Short-TE proton magnetic resonance spectroscopy investigation in adolescents with attention-deficit hyperactivity disorder. Psychiatry Research: Neuroimaging 2010, 181:199-203.
54. Yeo R.A., Hill D.E., Campbell R.A., Vigil J., Petropoulos H., Hart B., Zamora L., Brooks W.M. Proton magnetic resonance spectroscopy investigation of the right frontal lobe in children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42:303-310.
55. Ziskin J.L., Nishiyama A., Rubio M., Fukaya M., Bergles D.E. Vesicular release of glutamate from unmyelinated axons in white matter. Nature Neuroscience 2007, 10:321-330.